Surgical outcomes for gastric cancer patients with intraperitoneal free cancer cell, but no macroscopic peritoneal metastasis
Article first published online: 25 MAY 2011
Copyright © 2011 Wiley-Liss, Inc.
Journal of Surgical Oncology
Volume 104, Issue 5, pages 534–537, October 2011
How to Cite
Saito, H., Kihara, K., Kuroda, H., Matsunaga, T., Tatebe, S. and Ikeguchi, M. (2011), Surgical outcomes for gastric cancer patients with intraperitoneal free cancer cell, but no macroscopic peritoneal metastasis. J. Surg. Oncol., 104: 534–537. doi: 10.1002/jso.21983
- Issue published online: 6 SEP 2011
- Article first published online: 25 MAY 2011
- Manuscript Accepted: 4 MAY 2011
- Manuscript Received: 4 NOV 2010
- gastric carcinoma;
- intraperitoneal free cancer cell;
Background and Objectives
Gastric cancer patients with intraperitoneal cancer cells have extremely poor prognoses, because they frequently develop peritoneal metastasis. The aim of the current study is to clarify the clinicopathologic characteristics of patients with intraperitoneal free cancer cells who do not have recurrences.
This study examined 1,985 gastric adenocarcinoma patients who underwent gastrectomies at our institution between January 1975 and December 2000.
The 5-year survival rate of advanced gastric cancer patients with intraperitoneal free cancer cells, but no macroscopic peritoneal metastases (P0Cy1), is 15.3%. Multivariate analysis identified only lymph node metastasis as an independent prognostic indicator in P0Cy1 patients. The 5-year survival rates of P0Cy1 patients were 62.5%, 19.1%, 17.6%, and 9.4% in n0, n1, n2, and n3 patients, respectively. Peritoneal recurrence was observed significantly more often in P0Cy1 patients than in advanced gastric cancer patients without intraperitoneal free cancer cells.
Our data indicate that prognoses of P0Cy1 patients without lymph node metastasis are good, whereas the prognoses of those with lymph node metastasis are extremely poor. Therefore, radical surgery and adequate adjuvant chemotherapy should be performed for P0Cy1 patients with no lymph node metastasis. J. Surg. Oncol. 2011; 104:534–537. © 2011 Wiley-Liss, Inc.